Atherogenic properties of lipoproteins in HIV patients starting atazanavir/ritonavir or darunavir/ritonavir: a substudy of the ATADAR randomized study.
Saumoy, Maria; Ordóñez-Llanos, Jordi; Martínez, Esteban; Ferrer, Elena; Domingo, Pere; Ribera, Esteban; Negredo, Eugenia; Curto, Jordi; Sánchez-Quesada, José Luis; Di Yacovo, Silvana; González-Cordón, Ana; Podzamczer, Daniel.
J Antimicrob Chemother
; 70(4): 1130-8, 2015 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-25538166
[Adverse effects of antiretroviral agents, and their treatment].
Short-course antiretroviral therapy in primary HIV infection.
Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy.
HIV, highly active antiretroviral therapy and the heart: a cellular to epidemiological review.
Compliance with and outcomes of CD4-based national guidelines for prevention of mother-to-child transmission of HIV for Thailand, 2006-2007.
Monotherapy with boosted PIs as an ART simplification strategy in clinical practice.
Antiretroviral treatment French guidelines 2013: economics influencing science.
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART.
Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).
[Antiretroviral therapy of HIV infection].